Last reviewed · How we verify
Raltitrexed plus Docetaxel
Raltitrexed plus Docetaxel is a Small molecule drug developed by Hebei Tumor Hospital. It is currently in Phase 2 development.
Raltitrexed, a small molecule tubulin stabiliser, is combined with Docetaxel, another tubulin stabiliser, in a chemotherapy regimen. This combination is being studied in clinical trials for various conditions, including adenocarcinoma of the colon, rectum, and metastatic disease, as well as gastric cancer.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Raltitrexed plus Docetaxel |
|---|---|
| Sponsor | Hebei Tumor Hospital |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic (PHASE2)
- A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Raltitrexed plus Docetaxel CI brief — competitive landscape report
- Raltitrexed plus Docetaxel updates RSS · CI watch RSS
- Hebei Tumor Hospital portfolio CI
Frequently asked questions about Raltitrexed plus Docetaxel
What is Raltitrexed plus Docetaxel?
Who makes Raltitrexed plus Docetaxel?
What development phase is Raltitrexed plus Docetaxel in?
Related
- Manufacturer: Hebei Tumor Hospital — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing